Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on invested capital (ROIC) is N/A as of Tuesday, October 6, 2026.
RETURN ON INVESTED CAPITAL (ROIC)
N/A
Electra Therapeutics Inc.
Market Cap
$202.26M
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$206.04M
Return on Invested Capital (ROIC)
14.99%
TTM Avg
15.04%
3Y Avg
13.17%
5Y Avg
12.12%
Market Cap
$209.49M
Return on Invested Capital (ROIC)
-33.10%
TTM Avg
-20.50%
3Y Avg
-16.94%
5Y Avg
-23.40%
Market Cap
$194.56M
Return on Invested Capital (ROIC)
-20.24%
TTM Avg
-14.71%
3Y Avg
-27.01%
5Y Avg
-29.46%
Market Cap
$191.81M
Return on Invested Capital (ROIC)
-74.02%
TTM Avg
-48.91%
3Y Avg
-62.69%
5Y Avg
-47.07%
Market Cap
$214.34M
Return on Invested Capital (ROIC)
8.84%
TTM Avg
15.21%
3Y Avg
-9.34%
5Y Avg
-32.56%
Market Cap
$213.22M
Return on Invested Capital (ROIC)
26.14%
TTM Avg
3.79%
3Y Avg
-12.27%
5Y Avg
-17.37%
Market Cap
$214.21M
Return on Invested Capital (ROIC)
-43.74%
TTM Avg
-105.81%
3Y Avg
-81.36%
5Y Avg
-65.49%
Market Cap
$215.15M
Return on Invested Capital (ROIC)
-70.80%
TTM Avg
-76.09%
3Y Avg
-51.87%
5Y Avg
-42.00%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Electra Therapeutics Inc. (ETRA) | $202.26M | N/A | N/A | N/A | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $206.04M | 14.99% | 15.04% | 13.17% | 12.12% |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $209.49M | -33.10% | -20.50% | -16.94% | -23.40% |
| RxSight, Inc. (RXST)vs › | $194.56M | -20.24% | -14.71% | -27.01% | -29.46% |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $191.81M | -74.02% | -48.91% | -62.69% | -47.07% |
| Niagen Bioscience Inc (NAGE)vs › | $214.34M | 8.84% | 15.21% | -9.34% | -32.56% |
| Compugen Ltd. (CGEN)vs › | $213.22M | 26.14% | 3.79% | -12.27% | -17.37% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $214.21M | -43.74% | -105.81% | -81.36% | -65.49% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $215.15M | -70.80% | -76.09% | -51.87% | -42.00% |
| Alector, Inc. (ALEC)vs › | $218.62M | -71.04% | -53.65% | -40.34% | -35.55% |
ROIC
N/A
ROE
N/A
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
